Ma Songjiang's Form 4 filing
Gyre Therapeutics, Inc. (GYRE) · filed Mar 11, 2025
- Accession no.
- 0001140361-25-008091
- Filed
- Mar 11, 2025
- Trade date
- Mar 7-10, 2025
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 4 non-derivative transactions and 0 derivative transactions. Open-market sales total $40.8K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Ma SongjiangCIK 0001985547 | Director, Officer (President) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 7, 2025 | Common Stock | SSaleDisposed | −53 | $13.03 | −$690.59 | 2,843,207 | Indirect | |
| Mar 7, 2025 | Common Stock | SSaleDisposed | −41 | $12.14 | −$497.74 | 2,843,166 | Indirect | |
| Mar 7, 2025 | Common Stock | SSaleDisposed | −1,906 | $10.13 | −$19,307.78 | 2,841,260 | Indirect | |
| Mar 10, 2025 | Common Stock | SSaleDisposed | −2,000 | $10.14 | −$20,280 | 2,839,260 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.